Copyright ©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 323-334
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.323
Figure 1
Figure 1 Graphical summary of different responses to immunotherapy. Pseudoprogression: increase of longest diameter > 20% at first follow-up, followed by a decrease of > 30% at subsequent follow-up. Dissociated response: increase of some target lesions of > 20% and reduction of at least another target lesion > 30% at follow-up. Hyperprogression: significant increase of target lesion at first follow-up; a baseline study is needed to correctly assess the hyperprogression. T: Time; TV: Tumor volume.
Figure 2
Figure 2 Axial computed tomography images in the portal-venous phase of a 69 y/o male, ex-smoker with non-small lung cell carcinoma, during second-line therapy with Atezolizumab. A: Pre-treatment imaging show the right peri-hilar lesion; B: During follow-up after 4 wk the lesion increase in size; C and D: During the following computed tomography scans (8 and 12 wk) a significant decrease in longest diameter was achieved, confirming a final response to treatment with the presence of intercurrent (B) pseudoprogression.
Figure 3
Figure 3 Axial computed tomography images in the portal-venous phase of a 65 y/o female, with non-small lung cell carcinoma and a programmed death-ligand 1 expression > 90%, during first-line treatment with Pembrolizumab. A: In the baseline examination, computed tomography (CT) shows a metastatic lesion in the right adrenal gland; B: After 4 wk of treatment, the lesion becomes bigger, with a total increment of 21%, referred to as unconfirmed progression; C-E: during following CT scans, the target lesion shows a progressive dimensional reduction with a total decrease of 46%. These variations in the size of the lesion, during immunotherapy, was in line with pseudoprogression.
Figure 4
Figure 4 Axial computed tomography images in the portal-venous phase of a 57 y/o female ex-smoker with non-small lung cell carcinoma during second-line treatment with Pembrolizumab. Images show a dissociated response of two target lesions. A: The left peri-hilar lesion progressively decreased in size during follow-up, if compared to the pre-treatment computed tomography scan (after 3 wk and after 9 wk of immunotherapy from left to right, respectively); B: The second target lesion in left lung firstly regressed after 3 wk of immunotherapy showing, then a progression during the follow-up period (from left to right, respectively).